BUSINESSSTAT NEWS
STAT+: A prominent VC explains why she’s against U.S. restrictions on investment in China’s drug industry
Legislators are pushing to expand the COINS Act to include biotechnology, allowing the U.S. government to restrict investments in the Chinese biotech industry. Venture capitalist Julie Grant opposes these restrictions, arguing they would hinder U.S. drug development and harm patients by disrupting decades-long industry interdependencies.
Mentioned
Related Signal
Adjacent reporting
- Opinion: STAT+: Pharma and biotech leaders are destroying their own industry
- China’s biotech industry sees global expansion as unstoppable, despite US pressure
- China’s biotech industry sees global expansion as unstoppable, despite US pressure
- STAT+: Pharmalittle: We’re reading about U.S. biotech’s China problem, a Regeneron flop, and much more
- STAT+: Biotech veteran Jeremey Levin on why the industry’s future is secure, but American leadership is at risk
- Moolenaar Calls to Restrict American Investment in China’s Biotechnology Companies